





Cell Line Data Sheet for CHLA-12

Disease: Neuroblastoma

Phase of Therapy: Progressive disease at bone marrow transplant, post mortem

Treatment: N/A
Disease Stage: 4

Gender: Female
Age at diagnosis: NA
Race: N/A
Age at sample collection: N/A
Source of Culture: N/A

Primary Tumor Site: Bone Marrow

Date Established: N/A

MYCN Patient: Amplified MYCN Cell line: N/A

THmRNA: Expressed

p53 functionality: N/A
Telomere Mechanism: N/A
ALK: WT
RNAseq: N/A
WES: N/A

Growth Conditions: Please see Protocols section at https://www.cccells.org/protocols.php

5% CO₂, 20% O₂, 37.0°C

Media Formulation: Please see Protocols section at https://www.cccells.org/protocols.php

Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5

μg/mL insulin, 5 μg/mL transferrin, 5 ng/mL selenous acid)

Doubling Time: 65 hours

Growth Properties: Floating, some clumping/adhering together

STR Profile: May be obtained at https://strdb.cccells.org/

Notes: The Childhood Cancer Repository has a matching direct-to-culture diagnosis cell line available

from this same patient - CHLA-8 and CHLA-12. The repository has a matching EBV

lymphoblastoid cell line - COG-V-437

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis







Cell Line Data Sheet for CHLA-12

Cell Line Name: CHLA-12

Refrences:







Cell Line Data Sheet for CHLA-12

Cell Line Name: CHLA-12

